Dive into the science of precision cancer medicine at Knight School

Targeted therapy drugs have transformed the outlook for people diagnosed with one form of blood cancer, chronic myeloid leukemia. A disease with a three- to five-year life expectancy became, for...

Targeting osteosarcoma, a cancer more common in young people

Knight Cancer researchers describe positive results with the drug regorafenib. Osteosarcoma is a bone cancer that disproportionately affects teenagers, and despite substantial efforts, outcomes for...

Studies reveal new ways to fight a deadly leukemia

One study shows how it may be possible to stop acute myeloid leukemia by targeting a hidden population of cells that support the cancer. Another reveals how AML evolves to evade anti-cancer drugs,...

New path to stop drug-resistant breast cancer

Even when anti-cancer drugs appear to eliminate tumors, a resistant few malignant cells can survive and allow cancers to resume a fatal onslaught. Researchers at OHSU in Portland have revealed a...

Acclaim for a precision oncology pioneer in Oregon

Like few other drugs in the history of oncology, Gleevec transformed the outlook for patients: a disease with a life expectancy of less than five years – chronic myeloid leukemia – became a...

Cracking the code of advanced prostate cancer

Understanding the tumor-specific alterations that are most important for prostate cancer aggressiveness and treatment decision-making will be the focus of a Marquam Hill...

A new line of attack on deadly prostate cancers

Researchers have uncovered a potential drug target for stopping castration-resistant prostate tumors – the second leading cause of cancer death in the U.S. For decades, drug development for...

How to retarget cancers that have evaded targeted therapy

Targeted therapy drugs transformed the outlook for people with the rare cancers known as gastrointestinal stromal tumors, enabling some to survive a decade or longer. A fraction of GIST patients,...